Resultados de la búsqueda 161-170 of 10755 for valaciclovir

  1. Enfermedades infecciosas - Ensayos clínicos - Mayo Clinic

    The purposes of this study are to determine if patients treated with fluoroquinolone (FQ) antibiotics have depletion of mitochondrial DNA (mtDNA) in buccal ...

  2. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in ...

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic leukemia or ...

  4. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

  5. Hematología - Ensayos clínicos - Mayo Clinic

    Giving high dose chemotherapy followed by an autologous stem cell transplant may be more effective compared to observation only in treating patients with ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

  7. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...